-logo-1200x675.png?v=20240521153233&w=240&h=240&zc=2){kind=logo}
Repligen (NASDAQ:RGEN) Upgraded by Wolfe Research to Outperform Rating
Wolfe Research upgraded shares of Repligen (NASDAQ:RGEN – Free Report) from a peer perform rating to an outperform rating in a report published on Tuesday, Marketbeat.com reports. They currently have $160.00 price objective on the biotechnology company’s stock. A number of other research firms have also weighed in on RGEN. Royal Bank of Canada upped […]
Wolfe Research upgraded shares of Repligen (NASDAQ:RGEN – Free Report) from a peer perform rating to an outperform rating in a report published on Tuesday, Marketbeat.com reports. They currently have $160.00 price objective on the biotechnology company’s stock. A number of other research firms have also weighed in on RGEN. Royal Bank of Canada upped […]
